Trastuzumab (Herceptin) Enhances Class I-Restricted Antigen Presentation Recognized by HER-2/neu-Specific T Cytotoxic Lymphocytes
The DOI matches its Crossref record; 35 of the 35 references it cites were found in a registry or an index.
Abstract
PURPOSE: Numerous examples from animal models and clinical trials showed that HER-2-derived peptides are naturally processed as a CTL epitope and can be recognized by tumor-specific CTLs in several tumors with HER-2 overexpression. The humanized anti-HER-2 monoclonal antibody, Herceptin, has been designed to specifically antagonize the HER-2 function by directing against the extracellular domain of the HER-2 protein. One of the actions of Herceptin includes the internalization and degradation of HER-2, which might increase the amount of HER-2-derived peptides available for loading to MHC class I. EXPERIMENTAL DESIGN: In the present study, we investigated how Herceptin treatment of HER-2-overexpressing targets affects lysis by HER-2-specific CTLs. RESULTS: We showed that Herceptin sensitized HER-2-overexpressing tumors to lysis by HLA-A2-restricted or HLA-A24-restricted CTLs, without any effect of the expression of MHC class I, costimulatory molecules, adhesion molecules, or TAP-1 on the targets. Furthermore, the enhancement of cytolytic activity with Herceptin was inhibited by addition of a specific proteasome inhibitor, lactacystin. CONCLUSIONS: These results suggested that Herceptin treatment might enhance the class I-restricted presentation of endogenous HER-2 antigen via the proteasome step, resulting in higher susceptibility of HER-2-overexpressing tumors to lysis by the HER-2-specific CTLs.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“tation on MHC class I and II molecules (Kono et al., 2004; Triulzi et al., 2018), as well as MYD88 innate immune signal transduction adaptor (MYD88)-dependent immunostimulation (Stagg et al., 2011), culminating in increased antigen processing and presentation by DCs (Gall et al., 2017).”
From Immunomodulation by targeted anticancer agents (2021) · cites this paper as Kono et al., 2004
In the citing paper
“MHC class I and II upregulation in different HER2-overexpressing cancer cells and HER2 + BC biopsies”
From Immunomodulation by targeted anticancer agents (2021) · cites this paper as Kono et al., 2004
Citations
Cites
Slamon, D. J., Leyland-Jones, B., Shak, S., Fuchs, H., Paton, V., Bajamonde, A., Fleming, T., Eiermann, W., Wolter, J., Pegram, M., et al. (2001) · New England Journal of Medicine · doi:10.1056/nejm200103153441101 · Cited by 11,500
Studies of the HER-2/ neu Proto-Oncogene in Human Breast and Ovarian Cancer
Slamon, D. J., Godolphin, W., Jones, L. A., Holt, J. A., Wong, S. G., Keith, D. E., Levin, W. J., Stuart, S. G., Udove, J., Ullrich, A., et al. (1989) · Science · doi:10.1126/science.2470152 · Cited by 6,816
Rock, K. L., Gramm, C., Rothstein, L., Clark, K., Stein, R., Dick, L., Hwang, D., & Goldberg, A. L. (1994) · Cell · doi:10.1016/s0092-8674(94)90462-6 · Cited by 2,524
Coussens, L., Yang-Feng, T. L., Liao, Y.-C., Chen, E., Gray, A., McGrath, J., Seeburg, P. H., Libermann, T. A., Schlessinger, J., Francke, U., et al. (1985) · Science · doi:10.1126/science.2999974 · Cited by 1,814
Baselga, J., Tripathy, D., Mendelsohn, J., Baughman, S., Benz, C. C., Dantis, L., Sklarin, N. T., Seidman, A. D., Hudis, C. A., Moore, J., et al. (1996) · Journal of Clinical Oncology · doi:10.1200/jco.1996.14.3.737 · Cited by 1,380
Schwartz, R. H. (1992) · Cell · doi:10.1016/s0092-8674(05)80055-8 · Cited by 1,293 · cited 1×
“Effective CTL response requires both an antigen presentation delivered by antigenic peptides in the context of MHC class I molecules and costimulatory signals (19).”
DEGRADATION OF CELL PROTEINS AND THE GENERATION OF MHC CLASS I-PRESENTED PEPTIDES
Rock, K. L., & Goldberg, A. L. (1999) · Annual Review of Immunology · doi:10.1146/annurev.immunol.17.1.739 · Cited by 921
Nonclinical studies addressing the mechanism of action of trastuzumab (Herceptin).
Sliwkowski, M. X., Ja, L., Gd, L., Te, H., FENDLY, B. M., & Fox, J. A. (1999) · PubMed · Cited by 653
Brossart, P., Wirths, S., Stuhler, G., Reichardt, V. L., Kanz, L., & Brugger, W. (2000) · Blood · doi:10.1182/blood.v96.9.3102 · Cited by 552
Altered peptidase and viral-specific T cell response in LMP2 mutant mice
Van Kaert, L., Ashton-Rickardt, P. G., Eichelberger, M., Gaczynska, M., Nagashima, K., Rock, K. L., Goldberg, A. L., Doherty, P. C., & Tonegawa, S. (1994) · Immunity · doi:10.1016/1074-7613(94)90043-4 · Cited by 447
Cited by
Trastuzumab emtansine: mechanisms of action and drug resistance
Barok, M., Joensuu, H., & Isola, J. (2014) · Breast Cancer Research · doi:10.1186/bcr3621 · Cited by 595
The immune system and response to HER2-targeted treatment in breast cancer
Bianchini, G., & Gianni, L. (2014) · The Lancet Oncology · doi:10.1016/s1470-2045(13)70477-7 · Cited by 286
Czerniecki, B. J., Koski, G. K., Koldovsky, U., Xu, S., Cohen, P. A., Mick, R., Nisenbaum, H., Pasha, T., Xu, M., Fox, K. R., et al. (2007) · Cancer Research · doi:10.1158/0008-5472.can-06-4038 · Cited by 266
Barok, M., Isola, J., Pályi-Krekk, Z., Nagy, P., Juhász, I., Vereb, G., Kauraniemi, P., Kapanen, A., Tanner, M., Vereb, G., et al. (2007) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-06-0766 · Cited by 231
“restricted antigen presentation of ErbB2 (14).”
Barok, M., Tanner, M., Köninki, K., & Isola, J. (2011) · Breast Cancer Research · doi:10.1186/bcr2868 · Cited by 226
“Although the mechanisms underlying the action of trastuzumab are still not fully determined, its clinical benefit is attributed to internalization and down-regulation of cell surface HER2 [5], preventing the activation of AKT by reducing signaling in the PI3K-PTEN pathway [6], cell cycle arrest in G1 [7], HLA-I-restri…”
Background
Metadata
- Authors
- Kono, K., Sato, E., Naganuma, H., Takahashi, A., Mimura, K., Nukui, H., & Fujii, H.
- Affiliations
- University of Yamanashi Hospital (JP)
- University of Yamanashi (JP)
- 1First Department of Surgery, and
- Venue
- Clinical Cancer Research
- Published
- 2004-04-01
- Volume
- 10
- Issue
- 7
- Pages
- 2538-2544
- ISSN
- 1078-0432 (ISSN-L)
- 1557-3265
- OpenAlex
- W2144405588
- Cited by
- 59
- References
- 33
- Citations by year
- 2023: 1 · 2022: 5 · 2021: 1 · 2020: 1 · 2019: 1 · 2018: 2 · 2017: 3 · 2016: 3 · 2015: 2 · 2014: 4 · 2013: 2 · 2012: 3
- FWCI
- 1.68
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Clinical Cancer Research (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
- Health Sciences › Medicine › Oncology › HER2/EGFR in Cancer Research
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Keywords
- trastuzumab, HER2/neu, MHC class I antigen presentation, cytotoxic T lymphocytes, CTL epitopes, tumor cell lysis, proteasome, lactacystin, HLA-A2, HLA-A24, HER2 overexpression
- MeSH terms
- Trastuzumab, Acetylcysteine, Antibodies, Monoclonal, Epitopes, Antigens, Neoplasm, Antineoplastic Agents, Cytotoxicity, Immunologic, Coloring Agents, Enzyme-Linked Immunosorbent Assay, Flow Cytometry, Genes, MHC Class I, Humans, T-Lymphocytes, Cytotoxic, Blotting, Western, Histocompatibility Antigens Class I, Apoptosis, Annexin A5, Erb-b2 Receptor Tyrosine Kinases, Cell Line, Tumor, Proteasome Endopeptidase Complex, Antibodies, Monoclonal, Humanized, Proteasome Inhibitors
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Trastuzumab (Herceptin) Enhances Class I-Restricted Antigen Presentation Recognized by HER-2/neu-Specific T Cytotoxic Lymphocytes. https://app.cochat.ai/papers/10.1158/1078-0432.ccr-03-0424
- The paper
- Kono, K., Sato, E., Naganuma, H., Takahashi, A., Mimura, K., Nukui, H., & Fujii, H. (2004). Trastuzumab (Herceptin) Enhances Class I-Restricted Antigen Presentation Recognized by HER-2/neu-Specific T Cytotoxic Lymphocytes. Clinical Cancer Research. https://doi.org/10.1158/1078-0432.ccr-03-0424
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.